Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?

Jean-Michel Sallenave 1* and Loïc Guillot 2

1 INSERM UMR1152, Laboratoire d’Excellence Inflamex, Faculté de Médecine, Hôpital Bichat, Université de Paris, Paris, France, 2 Sorbonne Université, INSERM UMR S 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France

COVID-19 is caused by the Severe Acute Respiratory Syndrome (SARS) coronavirus (Cov)-2, an enveloped virus with a positive-polarity, single-stranded RNA genome. The initial outbreak of the pandemic began in December 2019, and it is affecting the health of the global community. In common with previous pandemics (Influenza H1N1 and SARS-CoV) and the epidemics of Middle east respiratory syndrome (MERS)-CoV, CoVs target bronchial and alveolar epithelial cells. Virus protein ligands (e.g., haemagglutinin or trimeric spike glycoprotein for Influenza and CoV, respectively) interact with cellular receptors, such as (depending on the virus) either sialic acids, Dipeptidyl peptidase 4 (DPP4), or angiotensin-converting enzyme 2 (ACE2). Host proteases, e.g., cathepsins, furin, or members of the type II transmembrane serine proteases (TTSP) family, such as Transmembrane protease serine 2 (TMPRSS2), are involved in virus entry by proteolytically activating virus ligands. Also involved are Toll Like Receptor (TLR) family members, which upregulate anti-viral and pro-inflammatory mediators [interleukin (IL)-6 and IL-8 and type I and type III Interferons among others], through the activation of Nuclear Factor (NF)-kB. When these events (virus cellular entry and innate immune responses) are uncontrolled, a deleterious systemic response is sometimes encountered in infected patients, leading to the well-described “cytokine storm” and an ensuing multiple organ failure promoted by a downregulation of dendritic cell, macrophage, and T-cell function. We aim to describe how the lung and systemic host innate immune responses affect survival either positively, through downregulating initial viral load, or negatively, by triggering uncontrolled inflammation. An emphasis will be put on host cellular signaling pathways and proteases involved with a view on tackling these therapeutically.

Keywords: COVID-19, SARS-CoV-2, coronavirus, protease, lung innate immunity

INTRODUCTION

COVID-19 is a respiratory disease whose aetiologic agent is a novel beta coronavirus (CoV) called Severe Acute Respiratory Syndrome (SARS)-CoV-2/2019-nCov. The initial outbreak of the pandemic began in December 2019, and it is currently affecting the health and safety of the global community. Indeed, on May 12, 2020, 4.5 million worldwide cases were confirmed (probably...
a significant under-estimation given the number of untested asymptomatic subjects), with a death toll exceeding 286,000. Before the SARS-CoV-2 outbreak, two related highly pathogenic CoVs viruses, Middle east respiratory syndrome (MERS)-CoV (1) and SARS-CoV (2), provoked catastrophic epidemics and pandemics, respectively. Unfortunately, no drugs nor vaccines have currently been approved to prevent or treat these viral episodes. The first anatomical/histological reports from the lungs of severely SARS-CoV-2-affected patients experiencing acute respiratory disease syndrome (ARDS) revealed excessive inflammatory activation and destruction of the bronchial and alveolar epithelium, features already observed during the first SARS pandemics in 2003 (3, 4). Indeed, in the latter pandemic, lung alveolar epithelial cells were identified as the most likely site of virus replication, and it was suggested that alveolar macrophages may be responsible for the dissemination of viruses within the lungs (3). In accordance, initial histological analyses of lung biopsies from patients positive for SARS-CoV-2 have shown exfoliation of the bronchial epithelium, which may induce altered mucociliary clearance and affect host immune responses (5).

Indeed, there is no doubt that the latter are involved in modulating disease onset and progression. For example, early studies report that, similarly with what was observed with SARS-CoV, lymphopenia [sometimes equivalent or more severe than that observed in human immunodeficiency virus (HIV) infection] is often observed in severely affected patients progressing to ARDS. Despite, or maybe correlated with this, aberrant non-effective innate immune host responses seem associated with severe lung disease during SARS (6–12).

The following sections will give an overview of the molecular and cellular mechanisms underpinning SARS-CoV virus infections and how lung and systemic host innate immune responses affect survival either positively, through downregulating the initial viral load, or negatively, by triggering uncontrolled inflammation. A particular emphasis will be put on the description of the host cellular signaling pathways and proteases involved with a view on tackling these therapeutically.

MECHANISMS OF ENTRY OF CORONAVIRUSES INTO TARGET EPITHELIAL CELLS (SEE FIGURE 1A)

Coronaviruses (CoVs) are enveloped viruses with a positive-polarity, single-stranded RNA genome encoding four structural proteins: the transmembrane trimeric spike glycoprotein (S), composed of two subunits S1 and S2), envelop (E), matrix (M), and nucleocapsid (N) (13).

The entry of CoV viruses into host epithelial cells is mediated by the interaction between the viral envelope S protein homotrimers and the cell surface receptors. Following proteolytic cleavage of the CoV S protein (“priming”), the S1 ecto-domain recognizes a membrane receptor [angiotensin-converting enzyme 2 (ACE2) for SARS-CoV and SARS-CoV-2 as well as Dipetidyl peptidase 4 (DPP4) for MERS-CoV], whereas the S2 C-terminal domain is involved in cell fusion and viral entry (14–16). This mechanism of action is very similar to that used by Influenza, except that the latter use sialic acids as the cognate receptor for its hemagglutinin (HA) ligand. Importantly, many viruses (Influenza, MERS, CoV, and Paramyxoviruses such as Hendra and Nipah viruses) use similar host proteolytic enzymes for cleaving their ligands (HA and S), namely, mostly lysosomal (Cathepsins B, L), furin, or trypsin-like proteases (17, 18). Indeed, it is believed that it is the cellular source of these proteases that may determine the infectivity spectrum of these viruses, with the lung and the gastro-intestinal tract being high producers (19, 20).

Although a variety of these proteases have been studied and shown to be involved to varying degrees in virus activation, including neutrophil elastase (21), proteases of the type II transmembrane serine proteases (TTSP) family [HAT, Transmembrane protease, serine (TMPRSS)2, and TMPRSS4] have recently been demonstrated to be particularly important, albeit probably at different stages of the virus cell cycle (19, 20, 22, 23). In particular, recent research on SARS-CoV-2 has focused on TMPRSS2 and has shown it to be important (although mostly using cell lines infected with pseudotyped virus particles bearing SARS-CoV-2 S protein) for virus entry (24, 25). In that context, it has also been demonstrated that the serine protease inhibitor camostat (see also below section on Therapeutic targets and Conclusion) was protective (24, 25). In contrast, DPP4 which is necessary for the entry of MERS-CoV (26, 27) is not involved in SARS-CoV-2 entry (24). Unlike other SARS-CoVs, the S protein of SARS-CoV-2 has a furin cleavage site at the boundary between the S1 and S2 subunits, which is processed during biogenesis and which may explain CoV-2 high infectivity (28). Although mechanistic studies are obviously still in their infancy, it is very likely that SARS-CoV and SARS-CoV-2 target mainly respiratory epithelial cells with similar mechanisms. Indeed, as indicated above, initial work has shown that ACE2 is the S receptor for both SARS-CoV (29) and SARS-CoV-2 viruses (24, 28, 30), and structural studies using cryo-electron microscopy suggest a binding of two S protein trimer to an ACE2 dimer (28, 30).

Whether this is strictly dependent on ACE2/protease expression is debatable since ACE2 is present in other tissues in humans [such as the intestine, kidney, and testis (31)]. Indeed, “seasonal” low pathogenic CoVs (e.g., CoV-229E, CoV-OC43) infect mostly upper airways, whereas pathogenetic CoVs (SARS-CoV/SARS-CoV-2 and MERS) have a tropism for the distal lung and can cause severe pneumonia and ARDS (32), as currently demonstrated again in the present pandemic. Indeed, potentially explaining this is the fact that seasonal coronaviruses do not use ACE2 as a receptor. In vitro, primary nasal and tracheobronchial

Abbreviations: CoV, Coronavirus; SARS, Severe Acute Respiratory Syndrome; MERS, Middle east respiratory syndrome; ARDS, acute respiratory disease syndrome; HIV, human immunodeficiency virus; S, Spike; E, envelop; M, matrix; N, nucleocapsid; HA, hemagglutinin; ACE2, angiotensin-converting enzyme 2; DPP4, Dipetidyl peptidase 4; TTSP, type II transmembrane serine proteases; TMPRSS, Transmembrane protease serine; NF-kB, Nuclear Factor; IL, interleukin; KO, knock-out; AT1, alveolar type I epithelial cell; ATII, alveolar type II epithelial cell; PRR, pattern recognition receptors; PAMPs, pathogen-associated molecular patterns; TLR, Toll-Like Receptors; IFN, interferon; Mac, macrophages; DCs, dendritic cells; PBMC, peripheral blood mononuclear cells; CCL2, C-C Motif Chemokine Ligand 2; C, ciliated; B, basal; G, glandular; CC, club cells; M, mucus; AM, alveolar macrophage; BCG, Bacille Calmette-Guérin.
epithelial cells as well as the Calu-3 bronchial cell line were shown to express ACE2 (the latter not colocalizing with cilia), and their infection with SARS-CoV was shown to be highly cytotoxic (33, 34). In the distal lung, as hinted above, primary alveolar type II epithelial (ATII) cells are also permissive to SARS-CoV infection (35, 36). SARS-CoV-2 has also been shown to infect various respiratory epithelial cell lines including A549 (alveolar origin), BEAS2-B (bronchial origin), Calu-3 cells, as well as primary human bronchial epithelial cells (24). Besides the lung, ACE2 is also highly expressed in the intestine (37), and gastrointestinal symptoms have been recorded with COVID-19 (38). It was shown that SARS-CoV2 is able to infect enterocytes as well as intestinal organoids and induces a viral response characterized by the expression of mediators related to type I and III IFN (39).

Even if SARS-CoV2 is thought to originate from bats, the intermediate host between bats and humans is still unknown. SARS-CoV was previously shown to infect various wild and domestic animals, including cats, ferrets and pigs (40–42).

Similarly, recent work reveals that domestic animals, including ferrets and cats, are permissive to SARS-CoV-2 infection. In contrast, the virus replicates poorly in pigs, ducks, chickens, and dogs (43).

Given the described importance of host proteases in mediating infectivity of a number of viruses, it is no surprise that, upon virus infection, murine knock-out (KO) has shown some protection. For example, TMPRSS2-KO mice were protected from pulmonary disease and death following H1N1 and H7N9 Influenza infection, but not from that of the influenza H3N2 subtype, demonstrating some specificity and showing also that other TTSP proteases [such as DESC1 (TMPRSS11E) and MSPL (TMPRSS13)] or other factors may be important (44–47). Similarly, TMPRSS2 KO mice showed reduced body weight and viral loads compared to WT mice in animals infected with SARS-CoV (48).

Also, it was demonstrated that over-expression of the human DPP4 in mice promoted MERS-CoV infection, causing lethal
disease (49), and that TMPRSS2 was instrumental in that context (48).

**ACTIVATION/MODULATION OF HOST SIGNALING PATHWAYS (SEE FIGURE 1A)**

**Epithelial Cells**

The control of viral infection requires an optimal and innate coordinated host antiviral immunity. This response is activated by various sensors, including pattern recognition receptors (PRR), which recognize pathogen-associated molecular patterns (PAMPs). Although for many viruses, viral RNA is a PAMP classically detected by different sensors, including Toll-Like Receptors (TLR)3 (which senses double stranded (ds)RNA), TLR7 and TLR8 (which sense single stranded (ss)RNA), RIG-I (which senses short dsRNA and ssRNA specific motifs), and MDA-5 (which senses long dsRNA) (50), the sensors potentially recognizing SARS-CoV genomic material are still elusive. In addition, although, as mentioned above, distal peripheral lung alveolar epithelial cells seem to harbor SARS-CoV infection in vivo, and although respiratory epithelial cells are known to express TLR3, TLR7, and TLR8 (51, 52) and initiate innate immunity in the lung (53), the study of these cells in anti-CoV responses has been hampered by their general poor permissibility to the virus in vitro (except for intestinal Caco-2 and HEK293 kidney epithelial cells) (54). In that respect, although the specific PRR involved was not identified, the M protein of SARS-CoV was indeed shown to induce interferon (IFN)-β in a TLR-related-TRAF3-independent mechanism in HEK293 cells (55). Regarding the lung, the differentiated Calu-3 cell line [when cultured at the air-liquid interface (ALI)] is the model of choice: in that set-up, SARS-CoV infection triggered an inflammatory response characterized by increased production of interleukin (IL)-6, IL-8, gamma interferon (IFN-γ), inducible protein 10 (IP-10), and activation of the transcription factor NF-κB (56). However, the kinetics of this response was extremely slow, and importantly, type I IFN, an important mediator of anti-viral responses, was undetected.

Also, another study involving A549 cells demonstrated that the trimeric spike S glyprotein and virus-like particles were able to modestly upregulate CCL2, an important monocyte chemokine (57).

In addition to lung epithelial cells cultured at ALI, precision-cut lung slices could also be an interesting tool to study SARS-CoV2-cells interactions (58), as demonstrated in Influenza infections with human (59) or animal-derived material (60).

As mentioned above, TTSPs can activate virus-ligands (HA and S protein), but they are also able to modulate cell signaling pathways. For example, recombinant HAT is able to activate mucin gene expression in NCI-H292 lung epithelial cells (61).

Relatedly, we have shown both in vitro in epithelial cells and in a murine model that Influenza H3N2 is able to upregulate mucin expression and that this is dependent on human (or mouse) HAT upregulation and TACE activity (62). Interestingly, Haga et al. have shown that inhibiting TACE prevents SARS-CoV cellular entry (63). Strengthening the signaling potential of the receptors, Iwata-Yoshikawa et al. demonstrated in vivo that poly IC (TLR3 ligand) induces the expression of a variety of pro-inflammatory mediators (CCL2, KC, and IL-1) through the expression of TMPRSS2 (48).

In addition, although unclear as whether it is beneficial or detrimental to the host cell, SARS-CoV have been shown to activate host stress response, apoptosis, and autophagy (13). These are also various pathways that may also need to be evaluated therapeutically in the context of the current pandemic. Relatedly, we have shown that chloroquine, which also inhibits the autophagic cellular flux by decreasing autophagosome-lysosome fusion, can inhibit Influenza-mediated CCL5 production (64).

Importantly, after having established a foothold in the epithelial compartment, SARS-CoV can disrupt the epithelial polarity, thereby getting access to the parenchyma tissue: for
example, it has been shown that the virus membrane protein E binds to PALSL1 (Protein Associated With Lin Seven 1), a junction protein involved in epithelial polarity, and modifies its cellular distribution at the surface of HEK-293 cells (65).

**Myeloid Cells and Myeloid-Epithelial Cells Interaction**

Myeloid cells, e.g., alveolar and interstitial macrophages or dendritic cells (DCs), elicit different immune responses toward influenza viruses, according to their subtypes (66). It is thus predictable that specificities may also exist with respect to SARS-CoV-2 infections. Indeed, although studies are scant, these cells have generally been shown to be poorly permissive to SARS-CoV replication (54, 67, 68).

However, a few studies have shown that myeloid cells can respond to SARS-CoV infection. Indeed, Dosch et al. showed that the S protein could, through TLR2, trigger NF-kB activation and inflammatory responses in peripheral blood mononuclear cells (PBMC) (69). Also, in common with epithelial cells, it was shown that PBMCs and DCs infected with SARS-CoV produced cytokines and chemokines such as C-C Motif Chemokine Ligand (CCL)-2 and/or C-X-C Motif Chemokine Ligand (CXCL)-10/RANTES/Tumor Necrosis Factor (TNF)/IL-8/IL-6, but, importantly, not IFN-γ (67, 68). By contrast, a study performed mostly on THP-1 macrophages suggest that MERS S protein suppresses macrophages pro-inflammatory responses through DPP4-induction of IRAK-M and PPARγ (70).

Furthermore, in an interesting “2-way” system involving differentiated SARS-permissive lung Calu-3 cells and monocyte-derived Macs and DCs, it was shown that mediators produced by Calu-3 cells activate cytokine production by macrophages (IL-1β, G-CSF, MIP-1, and TNF-α) and DCs (IL-12p40, MIP-1, IFN-γ, IL-6, IL-8, and MCP-1) but that some of these Calu-3 derived mediators (in particular IL-6 and IL-8) compromised the ability of DCs and Macs to activate naïve T cells and phagocytosis (4, 56). This echoes data obtained from patients suggesting that SARS may in fact be partly caused by a “paralysis” of the adaptive immune system, characterized by a diminished number of immune cell types including T lymphocytes, DCs and Macs (4).

**From Murine Models to Human Genetics**

Demonstrating that SARS-CoV can induce TLR-dependent host responses in vivo, Tlr4, Tlr3, and Tram KO mice were shown to be more susceptible to mouse-adapted SARS-CoV, albeit without exhibiting extra mortality (71). In comparison, mice deficient for the signaling molecule Trif were highly susceptible to CoV infections, exhibited diminished lung function, aberrant inflammatory responses, and importantly, higher mortality (71).

In addition, a mouse genetic study revealed that the TLR adaptor protein Ticiam2 was a susceptibility gene to SARS-CoV (72); mice KO for Ticiam2 (72), but also Myd88 (73), another TLR adaptor protein, were highly susceptible to a mouse-adapted SARS-CoV lung infection. Since polymorphisms of TLRs and Myd88 have been associated in humans with heightened sensitivity to a variety of pathogens (74), these studies, in addition to demonstrating the role of TLR pathways in the SARS-CoV infection, suggested a human genetic predisposition to SARS-CoV, and this could explain the variability of severity in patients with COVID-19 disease. Forthcoming human genetic studies from international collaborative efforts (https://www.covid19hg.org) could reveal genetic variants associated with SARS-CoV2 susceptibility, as in the gene encoding ACE2 as recently suggested (75). Indeed, ACE2 genetic variants may be associated with a modulated ACE2 protein expression, the SARS-CoV-2 receptor, which may explain in part patients’ susceptibility to infection. Genes associated with TLR pathways also represent good candidates, as demonstrated in other respiratory viral infection (e.g., influenza) where TLR3 variants (76) were shown to modulate its virulence.

**Maladaptive Activation of Innate Immune Responses (see Figure 1B)**

As already mentioned above, aberrant maladaptive innate immune host responses, including “cytokine storm” events, have been associated with severe lung disease and the development of ARDS during SARS and the COVID-19 current episode. Mechanistically, these events usually occur at a late stage of the disease, and several mechanisms have been proposed. In particular, a murine study has shown that a prolonged (albeit delayed, as demonstrated also in vitro, see above) type I IFN signaling was instrumental in triggering over-exuberant innate inflammatory monocytes–macrophages immune responses and an impaired virus-specific T-cell response (77).

In complement to the mechanism proposed above, increased lung inflammatory protease (neutrophil elastase and metalloprotease) activity has been demonstrated in ARDS (78, 79), with a concomitant imbalance between protease and protease inhibitors activity (80). In addition, although not yet measured, to our knowledge, in SARS murine models, we and others have shown increased protease-mediated lung damage in mice infected with Influenza (81–83). Additionally, in a MERS-CoV murine model, it was shown that excessive complement activation was partly responsible for exacerbated lung inflammation (84).

Lastly, “cytokines storm” may also result from SOCS (suppressors of cytokine signaling) inhibition (85). Indeed, upon Influenza infection, SOCS1 and SOCS3 were shown to reduce type I IFN antiviral responses in human bronchial epithelial cells (86). Also, SOCS4-deficient mice exhibited heightened sensitivity to Influenza infection (87). Studies about SOCS involvement during coronavirus infections are currently lacking and should therefore bring new interesting information.

**POTENTIAL THERAPEUTIC TARGETS AND CONCLUSION (SEE FIGURE 2)**

On May 12, 2020, using the term “COVID,” an unbiased search of already registered trials on https://clinicaltrials.gov/ retrieved 1,409 hits, and, when refined with “double blind/placebo,” 119 hits were found. Although the number of trials that are ongoing or “under recruitment” is expectedly very high, the range of molecules tested is relatively narrow and aimed at
targeting mainly antivirals. These include remdesivir (21 hits), lopinavir/ritonavir (also used in AIDS), as well as interferons (46 hits). Also falling in that category are trials testing molecules aiming to block viral entry at the cellular surface by targeting ACE-inhibitors (32 hits) or the membrane proteases of the TTSP family (see above) using camostat mesilate (5 hits). Repurposing of non-antiviral drugs may offer new promising options, such as with Ivermectin—an FDA-approved anti-parasitic drug widely available and recently shown to inhibit SARS-CoV-2 in vitro (88).

Because the virus load is not necessarily correlated with symptoms deterioration in SARS (the latter being often caused by worsening of inflammation at day 7–10 post onset of clinical signs), it follows that anti-inflammatory drugs could/should be prescribed during that stage of the disease (8).

In that context, “classical” anti-inflammatory drugs are indeed currently being tested against COVID-19 [e.g., methylprednisolone, budesonide, hydrocortisone, azithromycin, and non-steroidal anti-inflammatory drugs (NSAIDs)]. In addition, more specific agents are also being investigated, targeting either IL-β (anakinra, 13 hits), IL-6 signaling (Siltuximab/3 hits, Tocilizumab/42 hits, Sarilumab/13 hits), or CD24 (CD24Fc) with the main objective to modulate the “cytokine storm.”

However, chloroquine/hydroxychloroquine has, so far, undoubtedly taken the lion’s share (178 hits), and it has attracted a lot of media attention. In that respect, the results from an initial pan-European endeavor (“Discovery”), now conducted largely in France because of enrollment difficulties, are eagerly awaited. This drug has a “mixed” mode of action. Indeed, it acts as an anti-viral (presumably through inhibition of lysosomal enzymes requiring an acidic pH and of activation of endolysosomes, see above section “Mechanisms of entry”) and as an anti-inflammatory molecule, and it has notably been used in inflammatory rheumatic diseases (89). Despite a relative safe profile, having been administered to millions of people over the years, worries have nevertheless arisen about cardiac issues in many individuals with severe Covid-19, and this will have to be properly assessed (90).

Regardless, the ultimate prize in the fight against COVID-19 (or further SARS-CoV infections) undoubtedly lies with the future generation of effective vaccines and the development of neutralizing antibodies (91, 92).

Unfortunately, coronavirus vaccines in general have attracted less attention compared to the effort dedicated to vaccines against other potential pandemic viruses such as Influenza. For example, from 2012 onwards, few SARS-CoV vaccines reached phase 1 clinical trials for lack of interest from the pharmaceutical industry when it became evident that the virus was not making a “comeback” after its initial appearance. However, although probably too late for affecting the current “first wave” of SARS-CoV-2 pandemic, many pharmaceutical companies and research laboratories are now working on a plethora of vaccine formulations [for a review, see (91) and https://clinicaltrials.gov, the latter reporting so far 83 clinical trials on vaccines].

Indeed, in pre-clinical studies, the determination of cryo-EM structures of the SARS-CoV-2 S ectodomain trimer is providing a blueprint for the design of vaccines and inhibitors of viral entry (28). In this context, promising results show that murine polyclonal antibodies against S protein of SARS-CoV are able to elicit polyclonal antibody responses, preventing SARS-CoV-2 entry into cells, and thus indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination (28).

In addition to testing the best SARS-CoV-2 specific epitopes from the most suitable proteins (S, N, etc.) and way of administration (best vectors, etc.), it is important to select the best animal models. Although convincing murine studies are still pending, as indicated above in the section “Mechanisms of entry…”, studies in other animals investigated the virus susceptibility of chickens, ducks, dogs, pigs, cats, and ferrets, with the latter two being the most permissive (43). Further up in the phylogenetic scale, a recent study reported that an inactivated vaccine candidate for SARS-CoV-2 was protective in macaques (93).

Finally, large epidemiological studies have demonstrated that Bacille Calmette-Guerin (BCG) can heterologously protect against virus infections [e.g., yellow fever virus (94), probably by tapping on trained immunity mechanisms (95, 96)]. Using such adjuvant-mediated strategies against SARS-CoV-2 viruses may therefore be an exciting avenue worthwhile pursuing (97–99).

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

LG and J-MS received grants from the Faculté de Médecine Sorbonne Université (AAP COVID19 and Université de Paris (Fonds d’urgence SARS-CoV-2 et COVID-19), respectively. This manuscript has been released as a pre-print at OSF (100).

REFERENCES

1. Chafekar A, Fielding BC. MERS-CoV; understanding the latest human coronavirus threat. Viruses. (2018) 10:93. doi: 10.20944/preprints201711.0198.v2
2. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. (2003) 349:2431–41. doi:10.1056/NEJMra032348
3. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. (2003) 361:1773–8. doi: 10.1016/S0140-6736(03)1341/3-7
4. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. (2005) 202:415–24. doi:10.1084/jem.20050828
5. Yao XY, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. Zhonghua Bing Li Xue Za Zhi. (2020) 49:41–17. doi:10.3760/cma.j.cn112151-20200312-00193
6. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest.* (2020) 130:2620–9. doi: 10.1172/JCI137244

7. Gimazrell-Boullous EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe.* (2020). doi: 10.1016/j.chom.2020.04.009. [Epub ahead of print].

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

9. Lescure FX, Boudama L, Nguyen D, Parisey M, Wicky PH, Bebilli S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis.* (2020) 20:697–706. doi: 10.1016/S1473-3099(20)30290-0

10. Thervarajan I, Nguyen TH, O., Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nat. Med.* (2020) 26:453–5. doi: 10.1038/s41591-020-0819-2

11. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* (2020). doi: 10.1001/jamainternalmed.2020.0994. [Epub ahead of print].

12. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XF, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol.* (2020) 17:541–3. doi: 10.1016/j.cmi.2020.04.031

13. Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. *Annu Rev Microbiol.* (2019) 73:529–57. doi: 10.1146/annurev-micro-020518-115759

14. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. *Virus Res.* (2015) 202:120–34. doi: 10.1016/j.virusres.2014.11.021

15. Tortorici MA, Veesler D. Structural insights into coronavirus entry. *Adv Virus Res.* (2019) 105:93–116. doi: 10.1016/bs.avir.2019.08.002

16. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. MERS-CoV spike protein: Furin-like cleavage site absent in CoV of the same clade. *Cell Host Microbe.* (2013) 13:406–18. doi: 10.1016/j.chom.2013.02.011

17. Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. *J Biol Chem.* (2009) 284:23177–81. doi: 10.1074/jbc.R109.021906

18. Choi SY, Bertram S, Glowacka I, Park YW, Pohlmann S. Type II transmembrane serine proteases in cancer and viral infections. *Trends Mol Med.* (2009) 15:303–12. doi: 10.1016/j.molmed.2009.05.003

19. Bottcher-Friebertshauser E, Klenk HD, Garten W. Activation of influenza virus activating host proteases: identification, localization and characterization of viruses related to the SARS coronavirus from animals and in vitro pathogenesis in an animal model of the human conducting airway epithelium. *Pathog Dis.* (2013) 69:87–100. doi: 10.1111/2049-632X.12053

20. Garten W, Braden C, Arendt A, Peitsch C, Baron J, Lu Y, et al. Influenza virus activating host proteases: identification, localization, and inhibitors as potential therapeutics. *Eur J Cell Biol.* (2015) 94:375–83. doi: 10.1016/j.ejcb.2015.05.013

21. Matsuyama S, Imai Y, Tahara M, Kubota T, Anraku M, Abe M, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. *J Virol.* (2011) 85:13636–72. doi: 10.1128/JVI.03030-11

22. Bottcher E, Matrosovich T, Beyerle M, Klenk HD, Garten W, Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. *J Virol.* (2006) 80:9896–8. doi: 10.1128/JVI.01118-06

23. Bertram S, Glowacka I, Muller MA, Lavender H, Ginis K, Nehmeier I, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. *J Virol.* (2011) 85:13636–72. doi: 10.1128/JVI.03030-11

24. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven prototype inhibitor. *Cell.* (2020) 181:271–80.e8. doi: 10.1016/j.cell.2020.02.052
46. Tarnow C, Engels G, Arendt A, Schwalm F, Sediri H, Preuss A, et al. TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. *J Virol.* (2014) 88:744–51. doi: 10.1128/JVI.03799-13

47. Zmora P, Blázquez P, Moldenhauer AS, Welsch K, Nehmeier I, Wu Q, et al. DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry. *J Virol.* (2014) 88:12087–97. doi: 10.1128/JVI.01427-14

48. Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, et al. Innate immune response to H3N2 and H1N1 influenza virus infection in human DPP4 knockin mice. *Proc Natl Acad Sci USA.* (2017) 114:E3119–28. doi: 10.1073/pnas.1619019114

49. Li K, Wohlford-Lenane CL, Channappanavar R, Park JE, Earnest JT, Bair TW, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. *Proc Natl Acad Sci USA.* (2017) 114:E3119–28. doi: 10.1073/pnas.1619019114

50. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. *Proc Natl Acad Sci USA.* (2017) 114:E3119–28. doi: 10.1073/pnas.1619019114

51. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. *Proc Natl Acad Sci USA.* (2017) 114:E3119–28. doi: 10.1073/pnas.1619019114

52. Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. *Annu Rev Immunol.* (2018) 36:667–94. doi: 10.1146/annurev-immunol-042617-053309

53. Alsafadi HN, Uhl FE, Pineda RH, Bailey KE, Rojas M, Wagner DE, et al. Applications and approaches for 3D precision-cut lung slices. *Am J Respir Cell Mol Biol.* (2015) 52:470–8. doi: 10.1165/rcmb.2014-0338OC

54. Wang Y, Liu L. The membrane protein of severe acute respiratory syndrome coronavirus. *J Biol Chem.* (2010) 285:5571–80. doi: 10.1074/jbc.M410592200

55. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. Severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. *J Virol.* (2017) 91:2038–56. doi: 10.1128/JVI.01792-08

56. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. *J Virol.* (2019) 93:e01815-18. doi: 10.1128/JVI.01815-18

57. Tarnow C, Engels G, Arendt A, Schwalm F, Sediri H, Preuss A, et al. Innate immune response to a H3N2 subtype swine influenza virus in newborn porcine trachea cells, alveolar macrophages, and precision-cut lung slices. *Virology.* (2015) 483:305–16. doi: 10.1016/j.virol.2015.08.009

58. Gralinski LE, Menachery VD, Morgan AP, Tota Rugen Al-Qahtani AA, Lyroni K, Azaanourov M, Tsleiou M, Al-Anazi MR, Al-Ahdal MN, et al. Middle east respiratory syndrome coronavirus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. *Oncotarget.* (2017) 8:9053–66. doi: 10.18632/oncotarget.14754

59. Chokki M, Yamamura S, Eguchi H, Masegi T, Horiuchi H, Tanabe H, et al. Innate immune response to severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. *J Virol.* (2009) 73:7819–26. doi: 10.1128/JVI.01792-08

60. Lee CT, Fein AM, Lippmann M, Holtzman H, Kimbel P, Weinbaum G. Elastolytic activity in pulmonary lavage fluid from patients with acute respiratory distress syndrome. *Eur Respir J.* (2009) 33:1029–36. doi: 10.1183/09031936.99.13510299

61. Sallenave JM, Donnelly SC, Grant IS, Robertson C, Gauldie J, Hassett WP, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog.* (2008) 4:e1000240. doi: 10.1371/journal.ppat.1000240

62. Cook DN, Pisetys DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. *Nat Immunol.* (2004) 5:975–9. doi: 10.1038/nri1116

63. Lee CT, Fein AM, Lippmann M, Holtzman H, Kimbel P, Weinbaum G. Elastolytic activity in pulmonary lavage fluid from patients with acute respiratory distress syndrome. *Eur Respir J.* (2009) 33:1029–36. doi: 10.1183/09031936.99.13510299

64. Villaret B, Dieu A, Strabbe M, Solhonne B, Miklavc P, Hamadi S, et al. Silver nanoparticles impair retinoic acid-inducible gene i-mediated mitochondrial antiviral immunity by blocking the autophagic flux in lung epithelial cells. *ACS Nano.* (2018) 12:1188–202. doi: 10.1021/acsnano.7b06934

65. Teoh KT, Siu YL, Chan WL, Schutzer MA, Liu CJ, Petris JS, et al. The SARS coronavirus E protein interacts with PAL51 and alters tight junction formation and epithelial morphogenesis. *Mol Biol Cell.* (2010) 21:3838–52. doi: 10.1091/mbc.e10-04-0338

66. Duan M, Hibbs ML, Chen W. The contributions of lung macrophage and monocyte heterogeneity to influenza pathogenesis. *Immunol Cell Biol.* (2017) 95:225–35. doi: 10.1038/icb.2016.97

67. Cheung CY, Poon LL, Ng IH, Luk W, Sia SF, Wu MH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. *J Virol.* (2005) 79:7819–26. doi: 10.1128/JVI.79.12.7819-7826.2005

68. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. *Blood.* (2005) 106:2366–74. doi: 10.1182/blood-2004-10-4166

69. Villeret B, Dieu A, Strabbe M, Solhonne B, Miklavc P, Hamadi S, et al. Silver nanoparticles impair retinoic acid-inducible gene i-mediated mitochondrial antiviral immunity by blocking the autophagic flux in lung epithelial cells. *ACS Nano.* (2018) 12:1188–202. doi: 10.1021/acsnano.7b06934

70. Al-Qahtani AA, Lyroni K, Azaanourov M, Tsleiou M, Al-Anazi MR, Al-Ahdal MN, et al. Middle east respiratory syndrome coronavirus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. *Oncotarget.* (2017) 8:9053–66. doi: 10.18632/oncotarget.14754

71. Totura AL, Whitmore A, Agnihotram S, Scharf A, Katze MG, Heise MT, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. *MBio.* (2015) 6:e00638–15. doi: 10.1128/mBio.00638-15

72. Gralinski LE, Menachery VD, Morgan AP, Totura AL, Beall A, Kocher J, et al. Allelic variation in the toll-like receptor adaptor protein Tican2 contributes to SARS-coronavirus pathogenesis in mice. *G3.* (2017) 7:1653–63. doi: 10.1534/g3.117.014134

73. Sheehan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog.* (2008) 4:e1000240. doi: 10.1371/journal.ppat.1000240
82. Talmi-Frank D, Altboum Z, Solomonov I, Udi Y, Jaitin DA, Klepfish M, et al. Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality. Cell Host Microbe. (2016) 20:458–70. doi: 10.1016/j.chom.2016.09.005

83. Villeret B, Solhonne B, Straube M, Lemaire F, Cazes A, Garcia-Verdugo I, et al. Influenza virus pre-infection exacerbates Pseudomonas aeruginosa-mediated lung damage through increased MMP-9 expression, decreased eIF2α production and tissue resilience. Front Immunol. (2020) 11:117. doi: 10.3389/fimmu.2020.00117

84. Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. (2018) 7:77. doi: 10.1038/s41426-018-0063-8

85. Delgado-Ortega M, Marc D, Dupont J, Trapp S, Berri M, Meurens F, et al. SOCS proteins in infectious diseases of mammals. Vet Immunol Immunopathol. (2013) 151:1–19. doi: 10.1016/j.vetimm.2012.11.008

86. Poitlichet J, Chignard M, Si-Tahar, M. Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J Immunol. (2008) 180:2034–8. doi: 10.4049/jimmunol.180.4.2034

87. Kedzierski L, Linossi EM, Kolesnik TB, Day EB, Bird NL, Kile BT, et al. Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection. PLoS Pathog. (2014) 10:e1004134. doi: 10.1371/journal.ppat.1004134

88. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. (2020) 180:104787. doi: 10.1016/j.antiviral.2020.104787

89. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020) 16:155–66. doi: 10.1038/s41584-020-0372-x

90. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. (2020). doi: 10.1001/jamacardio.2020.1834. [Epub ahead of print].

91. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. (2020) 52:583–9. doi: 10.1016/j.immuni.2020.03.007

92. Jiang S, Hillyer C, Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. (2020) 41:355–9. doi: 10.1016/j.ti.2020.03.007

93. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. (2020) eabc1932. doi: 10.1126/science.abc1932. [Epub ahead of print].

94. Arts RJW, Moorlag S, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. (2018) 23:89–100 e105. doi: 10.1016/j.chom.2017.12.010

95. Netea MG, Joosten LAB. Trained immunity and local innate immune memory in the lung. Cell. (2018) 175:1463–5. doi: 10.1016/j.cell.2018.11.007

96. Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi-Shanjani M, Damjanovic D, et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell. (2018) 175:1634–50 e1617. doi: 10.1016/j.cell.2018.09.042

97. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsuchetsugu-Yokota Y, Sato Y, Morikawa S, et al. Effects of toll-like receptor stimulation on eosinophil infiltration in lungs of BALB/c mice immunized with UV-inactivated acute respiratory syndrome-related coronavirus vaccine. J Virol. (2014) 88:8597–614. doi: 10.1128/JVI.00983-14

98. Covian C, Retamal-Díaz A, Bueno SM, Kalergis AM. Could BCG vaccination induce protective trained immunity for SARS-CoV-2? Front Immunol. (2020) 11:970. doi: 10.3389/fimmu.2020.00970

99. Xing Z, Afkhami S, Bavananthasivam J, Fritz DK, D’Agostino MR, Vaseghi-Shanjani M, et al. Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies. J Leukoc Biol. (2020). doi: 10.1002/jlb.4MR0220-446R. [Epub ahead of print].

100. Sallenave JM, Guillot L. Host signaling and proteolytic pathways in the resolution or the exacerbation of coronavirus (CoV-2) infection in COVID-19 disease: what therapeutic targets? (2020) doi: 10.31219/osf.io/rtfmx

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Sallenave and Guillot. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.